Novelion Therapeutics Inc  

(Public, TSE:NVLN)   Watch this stock  
Find more results for TSE:QLT
-0.21 (-1.47%)
Feb 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 13.74 - 14.25
52 week 8.00 - 17.50
Open 14.10
Vol / Avg. 2,331.00/2,901.00
Mkt cap 256.63M
P/E     -
Div/yield     -
EPS -4.53
Shares 18.53M
Beta -0.41
Inst. own     -
Feb 23, 2017
Q4 2016 QLT Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -28.77% -15.06%
Return on average equity -30.77% -15.45%
Employees 23 -
CDP Score - -


887 Great Northern Way Suite 250
+1-604-7077000 (Phone)
+1-604-7077001 (Fax)

Website links


Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Officers and directors

Jason M. Aryeh Independent Chairman of the Board
Age: 47
Mary Szela Chief Executive Officer, Principal Executive Officer, Director
Gregory D. Perry Chief Financial and Administrative Officer
Age: 56
Barbara Y. Chan Chief Accounting Officer
Age: 53
Geoffrey F. Cox Ph.D. Director
Age: 72
Kevin Kotler Director
Jorge Plutzky Director
Sandford Smith Director
Donald Stern Director